OSR Holdings, Inc. entered into an Asset Purchase Agreement with its subsidiary, Vaximm AG, to acquire outright ownership of the VXM01 intellectual property family. The transaction involves an aggregate purchase price of $30,000,000, which becomes due upon the completion of a Phase 2 clinical study of VXM01 in either glioblastoma or pancreatic ductal adenocarcinoma.
